Premium
Induction intra‐arterial cisplatin and bleomycin in head and neck cancer
Author(s) -
Frustaci Sergio,
Barzan Luigi,
Caruso Giuseppe,
Ghirardo Riccardo,
Foladore Silva,
Carbone Antonino,
Comoretto Yroberto,
Serafini Italo,
Monfardini Silvio
Publication year - 1991
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.2880130405
Subject(s) - medicine , leukopenia , cisplatin , head and neck cancer , complete response , bleomycin , basal cell , catheter , peripheral , surgery , radiation therapy , anesthesia , gastroenterology , chemotherapy
Fifty‐two consecutive patients, affected by large T2 (>3 cm), T3, T4, N0, or N1 previously untreated squamous cell carcinoma of the head and neck, entered this phase I ‐ II study. Treatment consisted of a continuous 8‐day infusion on the following daily schedule: cisplatin 25 mg and bleomycin 15 mg administered for 4 and 20 hours, respectively. Technical‐related toxicities were 1 case each of coagulation and displacement of the catheter and 1 case of reversible monoparesis of the contralateral arm. Drug‐related relevant toxicities accounted for 4 cases of grade 3 or 4 leukopenia and 2 cases of peripheral palsy of the 7th and 12th cranial nerve, respectively. Forty‐five of 50 evaluable patients obtained an objective response. In particular, 13 patients obtained a complete response, 22 a partial response ⩾75%, and 10 a partial response ⩾50%. Furthermore, 5 of 31 patients showed a complete pathologic disappearance of the tumor, whereas in 12 of 31 only a microscopic residue was found.